Long-term safety of ziprasidone in schizophrenic patients: an open trial.

A Sciarretta, G Piazzi

Dipartimento di Salute Mentale, ASL Tivoli, Tivoli, Rome, Italy. an.sciarretta@libero.it

European review for medical and pharmacological sciences 2012 Dec

filter terms:

The Authors report the safety results of the extension phase of three multicenter, phase III studies, which evaluated ziprasidone in schizophrenic patients switching from another antipsychotic agent or who required a transition from intramuscular to oral ziprasidone. A total of 331 patients were evaluated, with a mean follow-up of 22 months (range: 3-73 months). Ziprasidone appeared well tolerated; most adverse events were of mild or moderate severity. No new safety or tolerability issues emerged. However, the authors observed a high number of withdrawals, possibly associated with a lack of long-term compliance, which is a common feature in schizophrenic patients.

Citation

A Sciarretta, G Piazzi. Long-term safety of ziprasidone in schizophrenic patients: an open trial. European review for medical and pharmacological sciences. 2012 Dec;16(15):2113-9